J. Oman Med. Assoc., Volume 2, Issue 1 (June 2025) – 4 articles

Human papillomavirus (HPV) infection poses significant public health issues for both men and women. Recent studies have brought attention to the substantial impact of HPV-linked cancers in men despite historically focusing more on its effects on women. It was revealed that in 2019, HPV was the root cause of approximately 70,000 cancer cases in men. Modes of transmission for HPV include sexual contact, encompassing various practices such as vaginal, anal, and oral intercourse, as well as the use of sexual devices. Moreover, HPV-associated cancers are becoming increasingly common in men, with anal, penile, and oral cancers being the most prevalent. Although the human body can clear HPV infection in about 90% of cases, it’s crucial to take preventive measures to lower the risk of transmission and developing cancer. Using condoms, quitting smoking, and male circumcision are identified as essential factors in preventing HPV among heterosexual couples. However, the most promising preventive measure is HPV vaccination. There are ongoing discussions regarding its protective efficacy and cost-effectiveness; vaccinating boys before their sexual debut presents a compelling rationale. The existing literature primarily focuses on HPV-linked cancer in women and lacks a comprehensive review of the development and prevention methods specifically related to HPV-related cancers in men. This review strives to bridge this gap by offering a detailed overview of HPV-linked cancers in males, particularly anal, penile, and head & neck cancer. It will cover important aspects of prevention and treatment strategies to provide valuable information for public health initiatives and clinical practice. Full article

Burn injuries cause severe muscle wasting and weakness. However, the relative contribution of neuromuscular junction (NMJ) degradation remains elusive. We investigated the associations of plasma c-terminal agrin fragment-22 (CAF22), a marker of NMJ degradation, with muscle decline in burn patients. We recruited male patients with burns (n = 32, age = 32.3 ± 4.5 years, percent burn area = 15.2 ± 2.3) and age-matched controls to evaluate handgrip strength (HGS), skeletal muscle mass index (SMI), phase angle, and creatine kinase and plasma levels of CAF22, c-reactive protein, and 8-isoprostanes. We used an unpaired t-test and regression analysis for statistics. The burn patients had lower HGS, SMI, and phase angle than the controls (all p < 0.05). These patients also exhibited higher plasma CAF22, CRP, 8-isoprostanes, and creatine kinase than the controls (all p < 0.05), suggesting NMJ degradation and heightened inflammation and oxidative stress. Correlation analysis revealed significant correlations of plasma CAF22 with HGS and phase angle in the burn patients, suggesting the potential contributions of NMJ degradation to muscle weakness and atrophy (both p < 0.05). We also found correlations of plasma CRP with HGS and phase angle in these patients (both p < 0.05). Altogether, NMJ degradation appears to play a significant role in burn-induced muscle injury and may warrant further investigation for potential therapeutic interventions. Full article

Numerous factors contribute to COVID-19 symptoms, with individuals who have pre-existing health conditions at the highest risk for severe SARS-CoV-2 infection. This study investigated the socio-demographic and comorbidity profiles within a large Turkish population diagnosed with SARS-CoV-2, including 47,875 patients diagnosed between March 2020 and May 2022 across six hospitals in different Turkish cities. Patients with SARS-CoV-2 confirmed via laboratory tests and presenting symptoms were included. The data collected covered socio-demographic details, infection onset dates, COVID-19 symptoms, pre-existing health conditions, radiological findings, treatments, disease progression, and relevant variables. A total of 47,875 files were included in the analysis. The median age was 43.7 years, with 84.5% testing positive for PCR SARS-CoV-2, often correlating with severe symptoms. Notably, 11.8% of the participants exhibited mild symptoms, and approximately 12.8% had comorbidities, increasing to 17.6% among severe cases. Females with PCR-positive COVID-19 had a comorbidity rate of 13.8%, compared to 12.5% in males. Among the patients with comorbidities, those aged 70 and above had the highest rates, at 22.1% (n = 1103). The most prevalent comorbidity was hypertension, followed by diabetes and cardiovascular diseases. Severe cases had a significantly higher prevalence of comorbidities (58.4%) compared to non-severe cases (27.6%). We hope that the evaluation of our findings will contribute to the research and treatment processes of the COVID-19 outpatients. Full article

This research aims to investigate the associations between comorbidities and clinical outcomes, specifically their impacts on mortality rates among COVID-19 inpatients, while also assessing the varying significance of different comorbidities. We conducted this study to understand the interplay between SARS-CoV-2 infection, socio-demographic factors, disease severity, and co-morbid conditions in a sample of 26,835 hospitalized COVID-19 cases. Our analysis extended to examining the frequency of infection symptoms, pre-existing health issues, treatment strategies, intensive care unit (ICU) and hospital stays, clinical symptoms, and radiological findings. Among the 26,883 cases analyzed, comprising 53.7% males and 53.3% females with an average age of 48.5 years, we observed mean clinical values for temperature, heart rate, respiratory rate, and blood pressure. Leveraging logistic regression modeling helped untangle the complex relationships and confounding variables influencing COVID-19 mortality. Notably, our findings underscored the significance of total length of stay, prolonged ICU stays exceeding ten days, and the presence of significant symptoms in affecting mortality rates among COVID-19 patients. These insights unveil potential trends crucial for informing future management strategies tailored to the needs of COVID-19 patients, emphasizing the importance of addressing comorbidities and optimizing care approaches for better outcomes. Full article